Compare BKSY & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | ABSI |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | 321 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 997.8M |
| IPO Year | N/A | 2021 |
| Metric | BKSY | ABSI |
|---|---|---|
| Price | $32.50 | $6.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $28.50 | $6.96 |
| AVG Volume (30 Days) | 2.3M | ★ 4.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | $27.03 | $215.96 |
| Revenue Next Year | $29.21 | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.12 | $2.24 |
| 52 Week High | $52.88 | $7.39 |
| Indicator | BKSY | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 59.06 |
| Support Level | $30.16 | $2.55 |
| Resistance Level | $42.75 | $7.06 |
| Average True Range (ATR) | 4.41 | 0.73 |
| MACD | -1.68 | -0.01 |
| Stochastic Oscillator | 11.81 | 69.70 |
BlackSky Technology Inc is a space-based technology company that delivers real-time imagery, analytics and high-frequency monitoring of the worlds critical and strategic locations, economic assets, and events. By taking a software-first technology approach, Company is delivering real-time space-based intelligence at disruptive speed, scale and economics. Companies single operating and reportable segment, provided space-based intelligence products and services through three integrated revenue streams-space-based intelligence & AI services, mission solutions, and technology programs. Geographically, the company operates in United States and Rest of world.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.